Surgical Repair vs. Non-Surgical Treatment for Rotator Cuff Tears: Is Surgery Worth the Cost?

By HEOR Staff Writer

January 28, 2023

The rotator cuff, a critical component of the shoulder, plays a crucial role in stabilising the joint and facilitating arm movement. When it tears, patients face a decision: to opt for surgical repair or non-surgical treatment. This rotator cuff repair analysis presents a detailed review of both methods, shedding light on their effectiveness, safety, and cost-effectiveness.

Understanding Rotator Cuff Tears

Low-to-moderate-certainty evidence suggests that surgical repair does not result in clinically relevant differences in effect compared to non-surgical treatment for degenerative rotator cuff tears. An HTA from the Norwegian institute of public health showed that choosing exclusively non-surgical treatment over surgery can provide up to NOK 81 million in annual cost savings.

Research suggests that there are no clinically relevant differences in effect between surgical and non-surgical treatment. Few serious adverse events were reported, but we are uncertain about the absolute risks. Surgery is the most expensive alternative, and choosing non-surgical treatment over surgery can provide significant cost savings.

Reference url

Recent Posts

Driving Economic Transformation through Brain Health Investment in Africa

By João L. Carapinha

January 9, 2026

The Johannesburg Communiqué from the Africa Task Force on Brain Health declares that investing in brain health is crucial, as it supports Africa’s economic transformation and Agenda 2063 goals while covering dementia, mental health, brain trauma, and substance abuse. This investment aligns with N...
NICE Endorses Natalizumab RRMS Treatment Expansion for Refractory Cases
NICE Expands Access to Natalizumab RRMS Treatment for Highly Active Cases The National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending natalizumab RRMS treatment o...
Johnson & Johnson’s EMA Application for Teclistamab Daratumumab Therapy: A New Hope fo...

By HEOR Staff Writer

January 8, 2026

Wondering how teclistamab daratumumab therapy could change treatment options for relapsed/refractory multiple myeloma? Johnson & Johnson recently filed a Type II variation application with the European Medicines Agency (EMA), which seeks to expand TECVAYLI® (teclistamab) combined with DARZALE...